Literature DB >> 8641620

Vulvar intraepithelial neoplasia in women infected with human immunodeficiency virus-1.

A P Korn1, P D Abercrombie, A Foster.   

Abstract

The purpose of this study was to determine the response of vulvar intraepithelial neoplasia (VIN) lesions to standard treatment methods in women infected with human immunodeficiency virus (HIV). We reviewed all cases of VIN over a 4-year period at an inner-city hospital. We reviewed the clinical records of these women to abstract demographic information as well as information about tobacco use, injection drug use, results of HIV testing, T cell count, stage of HIV infection, colposcopic and cytologic findings, treatment of lesions, and follow-up. Eight of the 28 women (29%) with VIN were infected with HIV. The relative risk for recurrence or persistence of VIN after treatment was 3.3 (95% confidence interval, 1.4-7.4; P = 0.01) in the HIV+ compared with the HIV- group. The high rate of HIV infection among women with VIN supports recommendation of HIV testing for women with VIN. Women known to have HIV infection should be carefully examined for vulvar lesions. Further study is needed to determine the optimum treatment for VIN in women infected with HIV.

Entities:  

Mesh:

Year:  1996        PMID: 8641620     DOI: 10.1006/gyno.1996.0161

Source DB:  PubMed          Journal:  Gynecol Oncol        ISSN: 0090-8258            Impact factor:   5.482


  2 in total

1.  The re-infection rate of high-risk HPV and the recurrence rate of vulvar intraepithelial neoplasia (VIN) usual type after surgical treatment.

Authors:  Antonio Frega; Francesco Sopracordevole; Paolo Scirpa; Alberto Biamonti; Laura Lorenzon; Simona Scarani; Luana De Sanctis; Arianna Pacchiarotti; Massimo Moscarini; Deborah French
Journal:  Med Sci Monit       Date:  2011-09

Review 2.  HPV Carcinomas in Immunocompromised Patients.

Authors:  Nicole M Reusser; Christopher Downing; Jacqueline Guidry; Stephen K Tyring
Journal:  J Clin Med       Date:  2015-01-29       Impact factor: 4.241

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.